134 related articles for article (PubMed ID: 36833984)
1. Predicting the Severity of Adverse Events on Osteoporosis Drugs Using Attribute Weighted Logistic Regression.
Ibrahim N; Foo LK; Chua SL
Int J Environ Res Public Health; 2023 Feb; 20(4):. PubMed ID: 36833984
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Statistical methods for exploring spontaneous adverse event reporting databases for drug-host factor interactions.
Lu Z; Suzuki A; Wang D
BMC Med Res Methodol; 2023 Mar; 23(1):71. PubMed ID: 36973693
[TBL] [Abstract][Full Text] [Related]
4. Likelihood ratio based tests for longitudinal drug safety data.
Huang L; Zalkikar J; Tiwari R
Stat Med; 2014 Jun; 33(14):2408-24. PubMed ID: 24919793
[TBL] [Abstract][Full Text] [Related]
5. Patients' preferences for anti-osteoporosis drug treatment: a cross-European discrete choice experiment.
Hiligsmann M; Dellaert BG; Dirksen CD; Watson V; Bours S; Goemaere S; Reginster JY; Roux C; McGowan B; Silke C; Whelan B; Diez-Perez A; Torres E; Papadakis G; Rizzoli R; Cooper C; Pearson G; Boonen A
Rheumatology (Oxford); 2017 Jul; 56(7):1167-1176. PubMed ID: 28398547
[TBL] [Abstract][Full Text] [Related]
6. How many deaths occur annually from adverse drug reactions in the United States?
Chyka PA
Am J Med; 2000 Aug; 109(2):122-30. PubMed ID: 10967153
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D.
Hara T; Hijikata Y; Matsubara Y; Watanabe N
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD013424. PubMed ID: 34231877
[TBL] [Abstract][Full Text] [Related]
8. ODAE: Ontology-based systematic representation and analysis of drug adverse events and its usage in study of adverse events given different patient age and disease conditions.
Yu H; Nysak S; Garg N; Ong E; Ye X; Zhang X; He Y
BMC Bioinformatics; 2019 May; 20(Suppl 7):199. PubMed ID: 31074377
[TBL] [Abstract][Full Text] [Related]
9. Quantifying the Severity of Adverse Drug Reactions Using Social Media: Network Analysis.
Lavertu A; Hamamsy T; Altman RB
J Med Internet Res; 2021 Oct; 23(10):e27714. PubMed ID: 34673524
[TBL] [Abstract][Full Text] [Related]
10. A Drug Safety Rating System Based on Postmarketing Costs Associated with Adverse Events and Patient Outcomes.
Hoffman KB; Dimbil M; Kyle RF; Tatonetti NP; Erdman CB; Demakas A; Chen D; Overstreet BM
J Manag Care Spec Pharm; 2015 Dec; 21(12):1134-43. PubMed ID: 26679963
[TBL] [Abstract][Full Text] [Related]
11. Counting the costs of drug-related adverse events.
White TJ; Arakelian A; Rho JP
Pharmacoeconomics; 1999 May; 15(5):445-58. PubMed ID: 10537962
[TBL] [Abstract][Full Text] [Related]
12. Oral Treatment With Bisphosphonates of Osteoporosis Does Not Increase the Risk of Severe Gastrointestinal Side Effects: A Meta-Analysis of Randomized Controlled Trials.
Dömötör ZR; Vörhendi N; Hanák L; Hegyi P; Kiss S; Csiki E; Szakó L; Párniczky A; Erőss B
Front Endocrinol (Lausanne); 2020; 11():573976. PubMed ID: 33240217
[TBL] [Abstract][Full Text] [Related]
13. Attribute Supervised Probabilistic Dependent Matrix Tri-Factorization Model for the Prediction of Adverse Drug-Drug Interaction.
Zhu J; Liu Y; Zhang Y; Li D
IEEE J Biomed Health Inform; 2021 Jul; 25(7):2820-2832. PubMed ID: 33373310
[TBL] [Abstract][Full Text] [Related]
14. Incidence and preventability of adverse drug events in nursing homes.
Gurwitz JH; Field TS; Avorn J; McCormick D; Jain S; Eckler M; Benser M; Edmondson AC; Bates DW
Am J Med; 2000 Aug; 109(2):87-94. PubMed ID: 10967148
[TBL] [Abstract][Full Text] [Related]
15. Systemic glucocorticoid therapy: risk factors for reported adverse events and beliefs about the drug. A cross-sectional online survey of 820 patients.
Morin C; Fardet L
Clin Rheumatol; 2015 Dec; 34(12):2119-26. PubMed ID: 25956956
[TBL] [Abstract][Full Text] [Related]
16. Chinese patients' preference for pharmaceutical treatments of osteoporosis: a discrete choice experiment.
Si L; Tu L; Xie Y; Palmer AJ; Gu Y; Zheng X; Li J; Lv Q; Qi J; Lin Z; Chen M; Gu J; Hiligsmann M
Arch Osteoporos; 2019 Jul; 14(1):85. PubMed ID: 31367860
[TBL] [Abstract][Full Text] [Related]
17. Patient preferences for osteoporosis in Spain: a discrete choice experiment.
Darbà J; Restovic G; Kaskens L; Balbona MA; Carbonell A; Cavero P; Jordana M; Prieto C; Molina A; Padró I
Osteoporos Int; 2011 Jun; 22(6):1947-54. PubMed ID: 20838770
[TBL] [Abstract][Full Text] [Related]
18. Predictors of serious adverse drug events from opioids: Results from the Food and Drug Administration Adverse Events Reporting System.
McDonald DD; Srisopa P
J Am Assoc Nurse Pract; 2021 Jan; 33(12):1207-1215. PubMed ID: 33534282
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous Adverse Events in Newly Approved FDA Non-cancer Drugs: A Systematic Review.
Macklis PC; Dulmage B; Evans B; Rosenbach M; Gudjonsson JE; Kaffenberger BH
Drugs R D; 2020 Sep; 20(3):171-187. PubMed ID: 32557274
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonates for steroid-induced osteoporosis.
Allen CS; Yeung JH; Vandermeer B; Homik J
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD001347. PubMed ID: 27706804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
